Paulson says Allergan could be wroth $220 per share, WSJ reports
John Paulson thinks Allergan (AGN) could be worth $220 per share if Valeant (VRX) is successful in acquiring the company, the Wall Street Journal reports, citing comments made at CNBC’s Delivering Alpha conference.